Anaconda Biomed announced the closing of a $56 million financing round with participation from new and existing investors. Proceeds will support product development and clinical work, including completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.
Anaconda’s proprietary Funnel Catheter platform is a novel endovascular technology designed to improve clot capture, reduce embolic complications and maximize rain reperfusion. In combining aspiration power with flow-arrest and flow-reversal, the platform may address clot retrieval, fragmentation and downstream embolization, taking on thrombectomy's most persistent challenges. Anaconda’s product portfolio will include supplementary tools such as stent retrievers, sheaths, and guidewires designed to complement the use of the funnel catheter technology and pave the way for additional clinical applications.
Anaconda targets a large, underpenetrated and expanding stroke intervention market. Strokes cause seven million deaths annually. Most of these (65%) are ischemic strokes, with 30% of these patients treated using mechanical thrombectomy. This translates to nearly 270,000 mechanical thrombectomy procedures performed globally in 2026, representing only a fraction of the total addressable market.
Anaconda has established a production facility on the edge of Barcelona. Direct control of the key development and manufacturing processes provides nimble, efficient and iterative product expansion capabilities. The company is establishing meaningful manufacturing trade secrets associated with its core technology.
